Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Autor:	Dimopoulos, Meletios A., Gay, Francesca, Schjesvold, Fredrik Hellem, Beksac, Meral, Hájek, Roman, Weisel, Katja Christina, Goldscmidt, Hartmut, Maisnar, Vladimir, Moreau, Philippe, Min, Chang Ki, Pluta, Agniezka, Chng, Wee-Joo, Kaiser, Martin, Zweegman, Sonja, Mateos, Maria Victoria, Spencer, Andrew, Iida, Shinsuke, Morgan, Gareth, Suryanarayan, Kaveri, Teng, Zhaoyang, Skacel, Thomas, Palumbo, Antonio, Dash, Ajeeta B., Gupta, Neeraj, Labotka, Richard, Rajkumar, Vincent
Zdroj:	Dimopoulos, Meletios A. Gay, Francesca Schjesvold, Fredrik Hellem Beksac, Meral Hájek, Roman Weisel, Katja Christina Goldscmidt, Hartmut Maisnar, Vladimir Moreau, Philippe Min, Chang Ki Pluta, Agniezka Chng, Wee-Joo Kaiser, Martin Zweegman, Sonja Mateos, Maria Victoria Spencer, Andrew Iida, Shinsuke Morgan, Gareth Suryanarayan, Kaveri Teng, Zhaoyang Skacel, Thomas Palumbo, Antonio Dash, Ajeeta B. Gupta, Neeraj Labotka, Richard Rajkumar, Vincent . Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet. 2018, 393(10168), 253-264 The Lancet
Databáze:	NORA (Norwegian Open Research Archive)
Externí odkaz:	http://hdl.handle.net/10852/72958 https://www.duo.uio.no/bitstream/handle/10852/72958/2/Dimopoulos-Rajkumar%2BMM3%2BLancet%2Bmanuscript%2Brevised%2B16Nov18_authors.pdf Zobrazit plný text záznamu